The estrogen sulfotransferase SULT1E1 sulfates and inactivates estrogen, which is reactivated via desulfation by steroid sulfatase, thus regulating estrogen homeostasis. Phenobarbital (PB), a clinical sedative, activates Sult1e1 gene transcription in mouse livers. Here, the molecular mechanism by which the nuclear receptors CAR, which is targeted by PB, and RORa communicate through phosphorylation to regulate Sult1e1 activation has been studied. RORa, a basal activity repressor of the Sult1e1 promoter, becomes phosphorylated at serine 100 and converts to an activator of the Sult1e1 promoter in response to PB. CAR regulates both the RORa phosphorylation and conversion. Our findings suggest that PB signals CAR to communicate with RORa via serine 100 phosphorylation, converting RORa from transcription repressor to activator of the Sult1e1 gene and inducing SULT1E1 expression in mouse livers.
The estrogen sulfotransferase SULT1E1 sulfates and inactivates estrogen, which is reactivated via desulfation by steroid sulfatase, thus regulating estrogen homeostasis. Phenobarbital (PB), a clinical sedative, activates Sult1e1 gene transcription in mouse livers. Here, the molecular mechanism by which the nuclear receptors CAR, which is targeted by PB, and RORa communicate through phosphorylation to regulate Sult1e1 activation has been studied. RORa, a basal activity repressor of the Sult1e1 promoter, becomes phosphorylated at serine 100 and converts to an activator of the Sult1e1 promoter in response to PB. CAR regulates both the RORa phosphorylation and conversion. Our findings suggest that PB signals CAR to communicate with RORa via serine 100 phosphorylation, converting RORa from transcription repressor to activator of the Sult1e1 gene and inducing SULT1E1 expression in mouse livers.
Keywords: CAR; nuclear receptors; phosphorylation; RORa; sulfotransferases Sulfotransferases (SULTs) are a family of cytosolic enzymes that transfer the sulfonate group from 3 0 -phosphoadenosine 5 0 -phosphosulfate to numerous endobiotics and xenobiotics [1] [2] [3] [4] . Estrogen sulfotransferase (SULT1E1 or EST) is the only enzyme that sulfates estradiol with high affinity and efficacy at nM Km [1, 5] . Sulfated estradiol is an inactive hormone and can be reactivated through desulfation by steroid sulfatase [6] [7] [8] [9] [10] . SULT1E1 is a key enzyme that maintain the metabolic homeostasis of estrogen activity [1, 11] . Thus, any disruption of its expression can be detrimental in estrogen-dependent biological processes as well as disease developments [12, 13] .
Nuclear receptors are known to regulate hepatic SULT1E1 expression [14, 15] , two of which are CAR and RORa. While SULT1E1 is barely expressed in the liver of normal C57BL/6 mice under normal feeding conditions, it becomes highly expressed in C57BL/6-derived diabetogenic/insulin insensitive (db/ db) or Staggerer mice [16, 17] . CAR activators, such as diallyl sulfide and 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), induced SULT1E1 in mouse livers [18, 19] . Insulin is known to repress CAR activation in mouse livers [20] . Staggerer mouse bear the mutated RORa gene that expresses the nonfunctional truncated RORa. Therefore, both CAR and RORa appeared to regulate the Sult1e1 gene. However, whether and how do the two nuclear receptors communicate to regulate the gene remains unexplored.
Abbreviations DBD, DNA-binding domain; FXR, farnesoid X receptor; PB, phenobarbital; SULTs, sulfotransferases.
Nuclear receptors possess highly conserved phosphorylation motif within their DNA-binding domain (DBD) in both mice and humans [21, 22] . CAR conserves this motif at threonine 38 and utilizes phosphorylation to regulate its activation [23] [24] [25] [26] . For example, phenobarbital, a widely used sedative drug, elicits an epidermal growth factor receptor-mediated cell signal that enables protein phosphatase 2A to dephosphorylate threonine 38 for CAR activation. Mouse estrogen receptor a conserves the corresponding motif at serine 216, which was found to be phosphorylated in immune cells such as neutrophils [27] . Farnesoid X receptor (FXR) became phosphorylated at serine 154 in response to its agonist in mouse livers and this phosphorylation was linked to FXR activation, inactivation, and degradation [21] . Thus, this conserved phosphorylation initiated the integration of the nuclear receptors as a common regulatory signal. RORa also contains this motif at serine 100, although phosphorylation of this residue has not yet been investigated.
In the present study, we have examined whether RORa regulates the Sult1e1 promoter through phosphorylation at its serine 100 and, if so, what is the role of CAR in this RORa-mediated regulation. Experiments utilized both Staggerer and CAR KO mice for in vivo studies including chromatin immunoprecipitation assays as well as phosphomimetic and non-phosphomimetic mutants of RORa (RORa S100D and RORa S100A, respectively) for Huh-7 cell-based reporter assays. A phospho-S100 peptide antibody was used to detect phosphorylation of RORa at serine 100. Experimental findings will be presented to characterize RORa as a transcriptional repressor and CAR as the master regulating the function of RORa through serine 100 phosphorylation to activate the Sult1e1 promoter in response to phenobarbital.
Materials and methods

Materials
Antibodies against RORa, #sc-6062 and #PP-H3910-00, were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and Perseus Proteomics, Inc. (Tokyo, Japan), respectively. A TOPO TA cloning kit with pCR2.1 TOPO and Power SYBR Green Master Mix were obtained from Invitrogen (Grand Island, NY, USA); an antibody to GFP-HRP (#ab6663) was from Abcam (Cambridge, UK); HRP-conjugated anti-FLAG M2 (S8592) was from Sigma-Aldrich (St. Louis, MO, USA). Anti-P-Ser100 peptide antibody (aP-Ser 100) against hRORa was generated by Genescript (Piscataway, NJ, USA Plasmids pGL3 vectors harboring mouse Sult1e1 promoter were constructed as described in our previous study [28] . Human RORa was subcloned into pCR2.1 vector from hRORaWT/pcDNA3.1, hRORa S100A/pcDNA3.1, and hRORa S100D/pcDNA3.1. RORE/p-tk-luc [29] was generously obtained from Anton Jetten, NIEHS. All constructs were verified by nucleotide sequencing. Luciferase reporter plasmid harboring the 237 bp (À167/ +87) of the mouse Sult1e1 promoter, named À167 bp, was constructed in pGL3 plasmid. Thirteen bps (À112/ À99) were internally deleted within the context of the À167 bp promoter to produce À167 bp ΔDR1 promoter.
Animals
Mice were maintained under the standard condition at the NIEHS. Animal experiments were conducted per protocols approved by the animal ethics committee at NIEHS/NIH. Both Car +/+ and Car À/À mice in C57BL/ 6 background were produced in house [30] . Staggerer mice (RORa sg/sg ) were obtained from the Immunity, Inflammation, and Disease Laboratory, NIEHS. Phenobarbital (100 mgÁkg À1 body weight) in PBS or PBS was intraperitoneally injected into 10-to 15-week-old male mice for 6 or 24 h.
Cell culture and transfection
The protocol used was detailed in our previous report [31] . Briefly, COS-1 cells grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS, penicillin (100 UÁmL
À1
) and streptomycin (100 lgÁmL À1 ) were transfected with given plasmids using FuGENE 6 Ò per manufacturer's instructions (Roche Diagnostics).
Real-time PCR (qPCR)
Total RNAs prepared from mouse livers was reverse transcribed using a High Capacity cDNA Archive kit (Life Technologies, Carlsbad, CA, USA). Taqman probes used were Mm00499178_m1 and Mm99999915_g1 for SULT1E1 and GAPDH, respectively. qPCR was performed with the CFX96 Touch Real-Time PCR Detection System (Bio-Rad).
ChIP assays
About 100 mg liver samples were sliced and incubated in a 1% formaldehyde for 10 min followed by a 5-min incubation in glycine at room temperature before homogenization. Nuclear suspensions were obtained by filtering homogenates through a Cell Strainer (Falcon), incubated in the lysis buffer, and sonicated as per manufacturer's guidelined (Activ motif). Immunoprecipitations were performed overnight with a RORa (#PP-H3910-00) antibody or a p-Ser100 using protein G conjugated magnetic beads. The beads were washed with ChIP buffers, chromatins were eluted, and the cross-linking was reversed prior to PCR (36 cycles) amplification using primers targeting the proximal region (À168/+68) of mouse Sult1e1 promoter.
Extraction of nuclear proteins
Huh-7 cells in a 10-cm dish were transfected with human RORa expression vectors (RORa WT/ pcDNA3.1, RORa S100A/pcDNA3.1 or RORaS100D pcDNA3.1) without or with mouse CAR. The cells were homogenized with a buffer consisting of 10 mM HEPES, pH 7.6, 10 mM KCl, and 1.5 mM MgCl 2 in the presence of 0.3% NP-40, and centrifuged at 2000 g for 5 min. The pellet was suspended in a lysis buffer composed of 10 mM HEPES, 100 mM KCl, 3 mM MgCl 2 , 0.1 mM EDTA, and 1 mM Na 3 VO 4 in 20% glycerol, and incubated at 4°C for 30 min after addition of 400 mM NaCl. The nuclear proteins were obtained by centrifuging the lysate at 62 744 g for 30 min.
Gel shift assays
Gel mobility shift assays were performed as described in our previous study [23] . Briefly, a 5 0 -overhanging double-stranded oligonucleotides were filled in with DNA polymerase Klenow fragment in the presence of [a- 
In vitro phosphorylation assays
GST-hRORa WT and its alanine mutant (RORa S100A) were bacterially expressed and purified for substrates through glutathione sepharose 4B (GE Healthcare, Chicago, IL, USA). These purified proteins (5 lg) were incubated with 50 mU of pure PKC in 30 lL of TBS buffer containing 2 mM CaCl 2 , 2 mM DTT, 17 mM MgCl 2 , 0.6 mgÁmL À1 phosphatidyl serine, and 170 lM ATP in the presence or absence of 0.5 lL (50 mU) of PKC at 30°C for 1 h for subsequent western blot analysis using aP-Ser100 antibody or anti-GST antibody in 5% BSA solution (1 : 500 dilution).
Western blot
Five microgram of RORa proteins for the in vitro phosphorylation assay or 5 lg for the Huh-7 cells nuclear contents were electrophoresed on a 10% SDS/ PAGE and transferred onto polyvinylidene difluoride membranes at 10 V or 15 V for 1 h. The membranes were probed with a given antibody overnight at 4°C, reacted with HRP-conjugated goat anti-rabbit (#Sc-2004), monkey anti-mouse (#Sc-2314), or donkey anti-goat IgG secondary antibodies using a WesternBright ECL or Sirius kit, and visualized by a C-DiGit Chemiluminescent Western Blot Scanner (LI-COR, Inc., Lincoln, NE, USA).
Co-IP assays
COS-1 cells cotransfected with given plasmids for 24 h were lysed in immunoprecipitation (IP) buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, protease inhibitors, and phosphatase inhibitor cocktails. Lysate was collected by centrifugation, sonicated, and resulted supernatants (500 lg protein) were incubated with anti-GFP antibody-conjugated agarose at 4°C for 4 h. Resins were washed with the IP buffer, subjected to SDS/PAGE for western blot analysis.
Reporter assays
COS-1 cells were cotransfected with a given RORa expression vector and p-tk-luc plasmids harboring RORE [29] and control Renilla luciferase plasmids for 24 h. Cell lysates were prepared to measure firefly luciferase activities using the dual luciferase assay system and normalized with Renilla luciferase activities.
Statistical analysis
The statistical significance was analyzed by multiple ttest (Holm-Sidak method) with a = 0.05 on GRAPHPAD PRISM software suite (La Jolla, CA, USA).
Results
SULT1E1 expression in mouse livers
The expression of mouse SULT1E1 mRNA was studied in mouse livers before or after phenobarbital treatment. First, CAR KO mice were utilized to examine how CAR regulated these expressions. The basal expression was increased over twofold in the liver of CAR KO mice. Phenobarbital treatment increased SULT1E1 mRNA levels about 20-fold in the liver of CAR WT mice, while the mRNA was not increased in that of CAR KO mice (Fig. 1A) . Subsequently, C57BL/6-derived RORa sg/sg mice, which lack functional RORa, and C57BL/6 (hereafter, just called RORa KO and WT for practical reason) were utilized. Levels of basal SULT1E1 mRNA expression were about 130-fold higher in the liver of RORa KO mice over the RORa WT mice (Fig. 1B) . Phenobarbital treatment increased SULT1E1 mRNA about 10-fold in the liver of RORa WT mice. About 4-fold increase was observed in RORa KO mice but was not statistically significant. Thus, the basal expression was repressed by both CAR and RORa, whereas the phenobarbital-induced expression depended on CAR and was significantly attenuated in the absence of RORa (Fig. 1A, B) .
Phosphorylation of serine 100
Since phenobarbital is known to regulate CAR through phosphorylation, we examined the hypothesis that RORa might also be regulated via phenobarbitalinduced phosphorylation, by focusing on the conserved phosphorylation motif within the DBD. RORa conserves this motif at serine 100 within its DBD (Fig. 2A) . Bacterially expressed recombinant RORa proteins were incubated with protein kinase C in in vitro kinase assays and were subjected to western blot analysis with aPSer100 antibody specific to RORa (Fig. 2B) . This antibody detected RORa WT but not RORa S100A, indicating that serine 100 was phosphorylated. Gel shift assays with in vitro translated RORa proteins showed that, consistent with phosphorylation (Fig. 2B) , RORa S100D was unable to bind a known response DNA element (RORE and HRE) for RORa binding (Fig. 2C) . Thus, RORa can be phosphorylated at serine 100, disabling its DNA-binding ability.
RORa regulation of the Sult1e1 promoter
Having these observations, the À167 bp Sult1e1 promoter was examined. This promoter was placed in front of luciferase reporter gene and coexpressed with RORa WT, non-phosphomimetic RORa S100A or phosphomimetic RORa S100D in COS-1 cells for subsequent luciferase assays (Fig. 3A) . While this promoter was highly active, it was effectively repressed by RORa WT and RORa S100A, but not RORa S100D (Fig. 3A) . Thus, RORa functioned as a repressor for the À167 bp Sult1e1 promoter in cell-based reporter assays. ChIP assays were employed to examine RORa binding to the Sult1e1 promoter in mouse livers before or after phenobarbital treatment. ChIP with an antiRORa antibody showed that RORa bound the promoter before treatment and continued to bind it even after treatment (Fig. 3B) . On the other hand, aPSer100 antibody detected RORa only after phenobarbital treatment (Fig. 3B) . The binding pattern before treatment was consistent with RORa that repressed the basal SULT1E1 mRNA expression in mouse livers. RORa appeared to become phosphorylated at serine 100 in response to phenobarbital; this phosphorylated RORa was retained on the promoter.
Our ChIP assays amplified the 236 bp (À168/+68) within which the À118/À94 bp region contains nested a ) mice (n = 3) were injected with PBS or 100 mgÁkg À1 PB for 24 h. The livers were collected and the total RNA was isolated for the cDNA synthesis. qPCR was performed for determination of Sult1e1 mRNA levels using GAPDH mRNA as endogenous control. The asterisk (*) between the groups represents statistically significant difference (*P < 0.05 and **P < 0.01) and ns stands for statistically insignificant differences (P > 0.05).
DR1 motif overlapped with an A/T-rich sequence, both of which can be RORa binding elements (Fig. 4A ). This DR-sequence was deleted within the context of the À167 bp promoter to examine whether RORa regulated the À167 bp Sult1e1 promoter activities through the motif in cell-based reporter assays. As expected, deletion disabled RORa WT and RORa S100A promoter regulation (Fig. 4B) . On the other hand, to our surprise, the RORa S100D mutant was found to activate this deletion promoter (Fig. 4B) . Apparently, this deletion may have created a promoter mimicking chromatin structure through which phosphorylated RORa activated the Sult1e1 promoter in mouse livers. This observation also revealed that the DR1 motif overlapped by A/T rich sequence was essential for the basal activity of the promoter. In addition to RORa, other nuclear factors may also bind this motif. For instance, [32] identified a DR4 motif overlapping the DR1 motif that can possibly bind CAR.
CAR regulation of RORa activities
Given the fact that RORa underwent phosphorylation to regulate the Sult1e1 promoter in response to phenobarbital, CAR KO mice were used to examine whether CAR was involved in this. First, gel shift assays were employed, for which nuclear extracts were prepared from Huh-7 cells transfected with RORa in the presence or absence of CAR. Nuclear extracts containing RORa S100A were most effectively shifted in the absence of CAR but were barely shifted in the presence of CAR (Fig. 4C) . Conversely, those containing the RORa S100D mutant greatly increased the shifted band in the presence of CAR (the right-side lane of Fig. 4C ). Although confirmation with supershift was not possible, a weak gel-shift band appeared with CAR-transfected extracts could be an indication of CAR binding to DR4. Western blots showed the expression levels of these proteins (Fig. 4D ). Since nuclear expression levels of RORa proteins were nearly identical in the presence or absence of CAR, these results suggested that CAR repressed RORa binding to the promoter while stimulated the binding of RORa S100D. Subsequently, ChIP assays were performed to examine RORa binding to Sult1e1 promoter in livers of CAR WT and CAR KO mice before or after phenobarbital treatment (Fig. 4E) . Confirming the observation in In vitro phosphorylation of the serine 100 for RORa by recombinant PKCs. GST-RORa was purified and used as the substrate. After phosphorylation, the proteins were subjected to western blotting using aP-Ser100 peptide antibody. (C) Gel shift assays. In vitro transcribed/translated proteins of hRORa was incubated with 32 P-labeled probe, electrophoresed on a polyacrylamide gel, and detected by autoradiography using a X-ray film. Probes used: 5 0 -GATCTCGACTCGTATATCAAGGTCATGCTG for RORE or 5 0 -GATCTCGACAGTGACCCTTTTAACCAGGTCAGTGAG. The À167 bp promoter or -Luc or the À167 bp DR1promoter-Luc was coexpressed with expression hRORa WT, RORa S100A, or hRORa S100D in COS-1 cells. Luciferase activities were normalized with Renilla luciferase activities. (C) RORa WT, RORa S100A, or RORa S100D was coexpressed in the absence or presence of ectopic CAR in Huh-7 cells for 48 h from which nuclear extracts were prepared and used in gel shift assays using oligonucleotide (À118/À94) as prob. (D) Nuclear extracts were subjected to western blot analysis to confirm expression levels of RORa proteins. (E) Chromatins were prepared from livers of CAR WT and CAR KO mice treated with PB for 6 h and subjected to ChIP assays as described in the Materials and methods section and in the legend of Fig. 3 . In the graph on the right side, the band intensities of PCR amplified DNAs for each group from two different samples immunoprecipitated by p-RORa were quantified by using gel imaging software (IMAGE J/NIH). The asterisk (*) between the groups represents statistically significant difference (*P < 0.05 and **P < 0.01).
in both before and after phenobarbital treatment. Moreover, aP-Ser100 peptide antibody detected RORa only after phenobarbital treatment. With CAR KO mice, it was found that a P-S100 peptide antibody, as well as a RORa antibody, detected RORa on the promoter before but not after treatment (Fig. 4E) . These observations suggested that CAR regulated phosphorylation and retained phosphorylated RORa on the promoter in response to phenobarbital.
Discussion
SULT1E1 mRNA augmented its basal expression and attenuated the rate of phenobarbital-induced increase in the liver of RORa KO mice. Consistent with its role as a transcription repressor, RORa was found to suppress the Sult1e1 promoter in cell-based reporter assays and was detected on the promoter in ChIP assays with mouse livers. RORa became phosphorylated at serine 100 and was retained on the activated Sult1e1 promoter in response to phenobarbital treatment, indicating the role of phosphorylated RORa as a transcription activator which was further confirmed by the finding that the phosphomimetic RORa S100D mutant activated the Sult1e1 promoter in cell-based reporter assays. Thus, phenobarbital-induced phosphorylation converted RORa repressing the Sult1e1 gene to activate it. Observations obtained with CAR KO mice demonstrated that CAR, acting as a master regulator, is essential for this conversion of RORa through serine 100 phosphorylation.
Serine 100 and threonine 38 are the conserved phosphorylation motifs within the DBDs of RORa and CAR, respectively. CAR inactivates its constitutive activation activity by phosphorylation at threonine 38. In response to phenobarbital, threonine 38 is dephosphorylated by protein phosphatase 2A to activate CAR [23, 24] . Conversely, it has now been determined that RORa becomes phosphorylated at serine 100 in response to phenobarbital. Therefore, RORa reciprocates serine 100 phosphorylation with CAR dephosphorylation at threonine 38 (Fig. 5) . In the absence of phenobarbital, CAR represses phosphorylation of serine 100 since this residue is phosphorylated in CAR KO mice before phenobarbital treatment. In the presence of CAR, serine 100 can only be phosphorylated in response to phenobarbital. Taken these observations in consideration, CAR phosphorylated at threonine 38 represses RORa phosphorylation at serine 100, enabling nonphosphorylated RORa to bind and repress the Sult1e1 promoter. Conversely, once threonine 38 dephosphorylated, CAR is no longer able to retain RORa in its nonphosphorylated form, disabling RORa's ability to repress the Sult1e1 promoter (Fig. 5) . The phosphorylated RORa remained on the promoter to activate it, by mostly likely acting as a coactivator, since phosphorylation inhibited direct DNA binding of RORa. Consistent with these observations, RORa S100D mutant activated the deletion promoter in reporter assays, which may have mimicked a state of the endogenous promoter. Both CAR and RORa are constitutive active nuclear receptors, for which the so-called Proposed mechanism for regulation of SULT1E1 expression by CAR and RORa. In this, the LBD of nuclear receptors are depicted in asymmetric shape. CAR utilizes different surfaces to form a homodimer and a heterodimer with RXR [25, 26] . Nonphosphorylated RORa binds and suppress the Sult1e1 promoter before PB treatment, although the possibility remains that this is an indirect binding through an additional protein. After PB, CAR become dephosphorylated at threonine 37 and retains RORa phosphorylated at serine 100 on the promoter as a coactivator. Whether phosphorylated RORa directly interacts with and coactivates CAR remains not yet proved. However, if it does, the CAR indicated as a PXR heterodimer in the hatched box may utilizes an opposite surface to interact with phosphorylated RORa. Our observations indicated phosphorylated CAR may prevent RORa from being phosphorylated. It remains elusive whether this prevention takes place either in the cytoplasm or in the nucleus, since CAR is phosphorylated in the cytoplasm as well as can be rephosphorylated in the nucleus [21] . Our ChIP assays also suggested that PB altered the Sult1e1 promoter in a CAR-independent manner. Our previous work demonstrated PB-induced but CAR-independent chromatin modification of the Cyp2b10 promoter [33] . Hatched arrow indicates such modification that may occur with the Sult1e1 promoter.
'endogenous ligands' equivalent to steroid hormones for nuclear hormone receptors may not be present. Instead, CAR and RORa utilize the common phosphorylation motif for their communication to activate the Sult1e1 promoter in response to phenobarbital. This concept of phosphorylation-mediated mechanism can be applied to many nuclear receptors which are constitutively activated.
Although the molecular mechanism utilized by CAR to regulate phosphorylation of RORa remains unexplored, the scenario of which may be speculated based on our previous findings. This conserved motif was first characterized as a site phosphorylated by protein kinase C (PKC) but can be phosphorylated by additional kinases. For example, p38 MAPK formed a complex with CAR and phosphorylated threonine 38 in the nucleus, suggesting that threonine 38 dephosphorylated in the cytoplasm can scaffold p38 MAPK in the nucleus [21] . p38 MAPK appeared also to phosphorylate RORa at serine 100 in in vitro kinase assays (Fig. S1 ). Moreover, CAR and RORa interacted as shown by co-immunoprecipitation assays (Fig. S2) . Thus, the scenario may be hypothesized that nonphosphorylated CAR scaffolds p38 MAPK to phosphorylate RORa at serine 100. To repress RORa phosphorylation, phosphorylated CAR may stimulate this phosphorylation or prevent it, the molecular mechanism for which remains beyond our speculation. Nevertheless, both CAR and RORa are colocalized in both phosphorylated and nonphosphorylated forms in the nucleus, possibly allowing them to communicate to regulate a gene. One outstanding question raised is how can CAR, RORa and likely protein kinase and phosphatase be compartmentalized on the promoter during these sequential processes.
In conclusion, the molecular mechanism by which phenobarbital utilizes two nuclear receptors to activate the Sult1e1 gene in mouse livers has now been described. In response to phenobarbital, CAR and RORa communicated through phosphorylation at the conserved site within their DBDs in this activation mechanism. Forty-one nuclear receptors conserve this phosphorylation motif and they may integrate this conserved phosphorylation as a communication language to form signal networks, regulating tremendously diversified biological functions.
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